Á lódáil...
N‐glycosylation of PD‐1 promotes binding of camrelizumab
PD‐1 is a highly glycosylated inhibitory receptor expressed mainly on T cells. Targeting of PD‐1 with monoclonal antibodies (MAbs) to block the interaction with its ligand PD‐L1 has been successful for the treatment of multiple tumors. However, polymorphisms at N‐glycosylation sites of PD‐1 exist in...
Na minha lista:
| Foilsithe in: | EMBO Rep |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe: |
John Wiley and Sons Inc.
2020
|
| Ábhair: | |
| Rochtain Ar Líne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7726772/ https://ncbi.nlm.nih.gov/pubmed/33063473 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15252/embr.202051444 |
| Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|